Mologen - Global lefitolimod partnership close to completion
Mologen announced that it has signed term sheets for a global partnership with Oncologie for its lead asset, lefitolimod. The deal is expected to...
74 Views
Mologen - IMPALA the focus as funding gap remains
Mologen’s Phase III pivotal trial (IMPALA) in metastatic colorectal cancer (mCRC) is now the focus for investors as both the Phase II trial...
78 Views
Mologen - Licensing and funding milestones in Q3
Mologen has announced two new sources of funding that will likely extend its cash reach into mid-2018. The signing of a share subscription facility...
92 Views
Lefitolimod trial readouts hint at future potential
In the last six months, mixed readouts in the Phase II SCLC trial (IMPULSE) and the Phase Ib/IIa HIV trial (TEACH) weighed on the stock. Full data...
84 Views
SCLC data - subgroup analysis hints at benefit
Top-line data from Mologen’s Phase II small cell lung cancer trial (IMPULSE) have been announced. Positive responses in two subgroups hint at a...
156 Views
No more insights